bitopertin
Phase 2- Indications
- Erythropoietic porphyria, Diamond-Blackfan Anemia
Company intelligence / Profile preview
Gemini Therapeutics
Cambridge, Massachusetts, United Statesgeminitherapeutics.com ↗
- Ownership
- Public · IRON
- Development stage
- Phase 2
01
Overview
Gemini’s lead asset GEM103—a recombinant human complement factor H—showed safety and no treatment-related adverse events in Phase I. The subsequent Phase IIa trial in geographic atrophy was terminated after failing to demonstrate additional clinical benefit.
- Therapeutic areas
- Ophthalmology
- Modalities
- AAV-based gene therapyRecombinant proteinsMonoclonal antibodiesLarge molecules (e.g., recombinant human complement Factor H)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
StrideBio for AAV vector developmentacademic collaborations for advanced research in gene editingpharmaceutical co-development partnerships for ocular therapeutics
04
Financials
- Market cap
- $3B
- Total revenue
- $0
- Enterprise value
- $2.3B
Beyond the preview
Go deeper on Gemini Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gemini Therapeutics.